Dermanolon 1.77 mg/ml + 17.7 mg/ml cutaneous spray, solution for dogs and cats

País: Irlanda

Língua: inglês

Origem: HPRA (Health Products Regulatory Authority)

Ingredientes ativos:

Triamcinolone acetonide; Salicylic acid

Disponível em:

Le Vet Beheer B.V.

Código ATC:

QD07XB02

DCI (Denominação Comum Internacional):

Triamcinolone acetonide; Salicylic acid

Dosagem:

1.77,17.7 milligram(s)/millilitre

Forma farmacêutica:

Cutaneous spray, solution

Tipo de prescrição:

POM: Prescription Only Medicine as defined in relevant national legislation

Grupo terapêutico:

Cats, Dogs

Área terapêutica:

triamcinolone

Indicações terapêuticas:

Corticosteroid

Status de autorização:

Authorised

Data de autorização:

2017-02-10

Características técnicas

Health Products Regulatory Authority
14 January 2022
CRN00CDZV
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Dermanolon 1.77 mg/ml + 17.7 mg/ml cutaneous spray, solution for dogs
and cats
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCES:
​
Triamcinolone acetonide
​
1.77 mg
​
Salicylic acid
​
17.7 mg
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Cutaneous spray, solution.
Clear colourless solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs and cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Symptomatic treatment of seborrhoeic dermatitis
4.3 CONTRAINDICATIONS
Do not use in cases of hypersensitivity to corticosteroids, salicylic
acid or to any of the excipients
Do not use on cutaneous ulcers.
Do not use in dogs with demodicosis.
Do not administer to animals weighing less than 3.5 kg body weight.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
At the beginning of treatment, existing scale and or exfoliative
debris should be removed. Hair surrounding or covering the
lesions may need to be clipped to enable the veterinary medicinal
product to reach the affected skin.
Seborrhoeic dermatitis may be a primary disorder, but can also occur
as a result of underlying disorders or disease processes
(e.g. allergic disorders, endocrine disorders, neoplasia).
Furthermore, infections (bacterial, parasitic or fungal) commonly
occur
concurrently with seborrhoeic dermatitis. Therefore it is essential to
identify any underlying disease process and initiate specific
treatment if considered necessary.
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
As the minimum bodyweight for the treatment is 3.5 kg, this product
will not be suitable for use in certain patients, such as
smaller dogs and cats or those with extensive lesions. Please check
maximum recommended dose in section 4.9.
Systemic corticosteroid effects are possible, especially when the
product is used under an occlusive dressing, on e